4a7a

Crystal structure of human monoamine oxidase B (MAO B) in complex with rosiglitazone

spinqualitylabelsall models 4a7a, resolution 1.70Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image   Print3D Structural highlights 4a7a is a 2 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance. Ligands: FAD, RGZ Related: 2c67, 3zyx, 1s3e, 2c73, 2v60, 1oj9, 1ojd, 2vz2, 1s3b, 2c66, 2xfo, 2bk5, 2c70, 1h8r, 2xfn, 2bk3, 2c76, 2vrl, 1oja, 2v5z, 2xfu, 2byb, 2vrm, 2c65, 2xcg, 2c64, 2xfp, 2bk4, 2c75, 2v61, 2c72, 1s2y, 4a79, 1gos, 1s2q, 2xfq, 1ojc Activity: Monoamine oxidase, with EC number 1.4.3.4 Resources: FirstGlance, OCA, RCSB, PDBsum Function [AOFB_HUMAN] Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine. Publication Abstract from PubMed The widely employed anti-diabetic drug pioglitazone (Actos) is shown to be a specific and reversible inhibitor of human monoamine oxidase B (MAO B). The crystal structure of the enzyme-inhibitor complex shows the R-enantiomer is bound with the thiazolidinedione ring near the flavin. The molecule occupies both substrate and entrance cavities of the active site establishing non-covalent interactions with the surrounding amino acids. These binding properties differentiate pioglitazone from the clinically used MAO inhibitors, which act through covalent inhibition mechanisms and do not exhibit a high degree of MAO A versus B selectivity. Rosiglitazone (Avandia) and troglitazone, other members of the glitazone class, are less selective in that they are weaker inhibitors of both MAO A and MAO B These results suggest that pioglitazone may have utility as a "re-purposed" neuro-protectant drug in retarding the progression of disease in Parkinson's patients. They also provide new insights for the development of reversible isoenzyme-specific MAO inhibitors. Molecular Insights into Human Monoamine Oxidase B Inhibition by the Glitazone Anti-Diabetes Drugs.,Binda C, Aldeco M, Geldenhuys WJ, Tortorici M, Mattevi A, Edmondson DE ACS Med Chem Lett. 2011 Oct 15;3(1):39-42. PMID:22282722 From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See Also Monoamine oxidase

Proteopedia Page Contributors and Editors (what is this?)

OCA